Market Overview

The Medicines Company Reports First-Quarter 2018 Results

Share:

The Medicines Company (NASDAQ:MDCO) today reported its financial
results for the first quarter ended March 31, 2018.

"During the first quarter of 2018, The Medicines Company continued to
demonstrate strong clinical and operational execution, significantly
advancing the ORION development programs for our investigational agent,
inclisiran, and delivering against all of our other 2018 objectives,"
said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The
Medicines Company.

First quarter 2018 highlights included:

  • In January, the Company completed the sale of its infectious disease
    business unit to Melinta Therapeutics, Inc. ("Melinta"), significantly
    strengthening the Company's cash position and substantially reducing
    its cost structure.
  • In January, the Company achieved target enrollment in the ORION-11
    Phase III clinical trial for inclisiran in patients with
    atherosclerotic cardiovascular disease (ASCVD) or cardiovascular
    risk-equivalents, randomizing more than 1,500 patients in only 11
    weeks – 14 weeks ahead of schedule. ORION-11, together with the
    ORION-9 and ORION-10 clinical trials, comprise the pivotal trials with
    18-month follow-up (collectively, the "ORION Pivotal Trials") designed
    to confirm inclisiran safety and efficacy, as well as provide data
    required for New Drug Application ("NDA") and Marketing Authorization
    Application ("MAA") submissions in the United States and Europe,
    respectively.
  • In January, the ORION Drug Safety Monitoring Board (the "DSMB") met to
    review data from the ORION Pivotal Trials and recommended that they
    continue without change or modification.
  • In January, the Company announced that it had achieved commercial
    scale manufacturing for inclisiran.
  • In January, the U.S. Food and Drug Administration (the "FDA") granted
    orphan drug designation to inclisiran for the treatment of homozygous
    familial hypercholesterolemia ("HoFH").
  • In February, the Company reached its enrollment target for the ORION-9
    clinical trial in patients with heterozygous familial
    hypercholesterolemia ("HeFH"), enrolling 400 patients in only 10 weeks
    – 14 weeks ahead of schedule.
  • In March, the Company reached its enrollment target for the ORION-10
    clinical trial in patients with ASCVD, randomizing more than 1,500
    patients in only 12 weeks –10 weeks ahead of schedule, completing
    enrollment in the ORION Pivotal Trials.
  • In March, the ORION DSMB met for the second time to review data from
    the ORION Pivotal Trials and recommended that they continue without
    change or modification.
  • In March, the Company hosted a major scientific symposium at the
    American College of Cardiology 2018 Annual Meeting in Orlando,
    Florida. During the symposium, which was co-chaired by Eugene
    Braunwald, M.D., Distinguished Hersey Professor of Medicine at Harvard
    Medical School and founding Chairman of the Thrombolysis in Myocardial
    Infarction (TIMI) Study Group, and John J.P. Kastelein, M.D., Ph.D.,
    Professor of Medicine and Chairman of the Department of Vascular
    Medicine at the Academic Medical Center of the University of
    Amsterdam, the design of the Company's ORION-4 cardiovascular outcomes
    trial was presented and Dr. Braunwald presented the case for
    primordial prevention of coronary disease with one, annual 300 mg
    injection of inclisiran.
  • Recently, the Company successfully completed manufacturing of its
    first batch of pre-filled syringes – the same syringe that will be
    used for inclisiran launch, and which will now be used in a portion of
    the ORION Pivotal Trials.
  • Over 50% of patients in the ORION Pivotal Trials have now received the
    second dose of inclisiran at Day-90, increasing by tenfold the number
    of patients receiving two doses of inclisiran over the
    previously-completed ORION-1 Phase II trial.
  • To date, the Company has accumulated more than 1,000 patient years of
    safety data for inclisiran.
  • During the first quarter of 2018, the Company substantially completed
    the implementation of its previously-announced restructuring, with all
    remaining restructuring activities, primarily consisting of the
    divestiture or separation of the pre-clinical infectious disease
    business not acquired by Melinta and the full wind down of all legacy
    businesses and assets, expected to be completed by June 30, 2018, as
    anticipated.

Commenting further, Dr. Meanwell said, "We fully expect to continue our
significant clinical and operational momentum throughout 2018 and into
2019, further demonstrating and enhancing inclisiran's unique and
potentially game-changing attributes. Based on the accelerated pace of
our development program, we expect clinical data readout for all four
ORION Pivotal Trials, as well as NDA and MAA submissions, in the second
half of 2019. We are also very satisfied with our progress in focusing
the Company on inclisiran and – after one-time restructuring and other
costs incurred during the first quarter of 2018, plus additional
one-time costs anticipated in the second quarter, as previously
announced – recurring savings in our operating expenditures, which will
become very clear by the second half of 2018. Our financial results for
the first quarter of 2018 met or exceeded all of our goals, and we will
continue to reduce expenses in all other areas of the Company to enable
us to fund the optimal development of inclisiran and, thereby, create
substantial shareholder value."

First-Quarter 2018 Financial Summary from Continuing Operations

On a GAAP basis, loss from continuing operations in the first quarter of
2018 was $84.8 million, or $1.14 per share, compared to $71.0 million,
or $1.00 per share, in the first quarter of 2017. Included in loss from
continuing operations for the first quarter of 2018 was a non-cash,
mark-to-market change in fair value of approximately $30.0 million
associated with the Company's common stock ownership in Melinta. On a
non-GAAP basis, adjusted loss (1) from continuing operations
in the first quarter of 2018 was $56.4 million, or $0.76(1)
per share, compared to $53.3 million, or $0.75(1) per share,
in the first quarter of 2017.

(1) Adjusted net loss and adjusted loss per share from
continuing operations are non-GAAP financial performance measures with
no standardized definitions under U.S. GAAP. For further information and
a detailed reconciliation, refer to the "Non-GAAP Financial Performance
Measures" and "Reconciliations of GAAP to Adjusted Loss from Continuing
Operations and Adjusted Loss per Share" sections of this press release.

First-Quarter 2018 Financial Summary from Discontinued Operations

In the first quarter of 2018, the Company completed the sale of its
infectious disease business, consisting of the products Vabomere™,
Orbactiv® and Minocin® IV, as well as line
extensions of those products, for $270 million in upfront consideration
and guaranteed payments ($215 million of guaranteed cash and Melinta
common stock with a closing date value of approximately $55 million),
tiered royalty payments of between 5% to 25% on worldwide net sales of
Vabomere, Orbactiv and Minocin IV, and the assumption by Melinta of all
royalty, milestone and other payment obligations relating to those
products.

Net income from discontinued operations in the first quarter of 2018 was
$114.0 million compared to a net loss of $31.7 million in 2017. Net
income from discontinued operations in the first quarter of 2018
includes a gain of approximately $169.0 million from the sale of the
Company's infectious disease business to Melinta.

At March 31, 2018 the Company had $216.0 million in cash and cash
equivalents, compared to $151.4 million at the end of 2017.

First-Quarter 2018 Conference Call and Webcast Information

The Company will host a conference call and webcast today, April 25,
2018, at 8:30 a.m., Eastern Daylight Time, to discuss its first-quarter
2018 financial results and provide clinical and operational updates. The
dial-in information to access the call is as follows:

U.S./Canada: (877) 359-9508

International: (224) 357-2393

Conference ID: 5683598

A taped replay of the conference call will be available from 11:30 a.m.,
Eastern Daylight Time, today until 11:30 a.m., Eastern Daylight Time, on
May 2, 2018. The replay may be accessed as follows:

U.S./Canada: (855) 859-2056

International: (404) 537-3406

Conference ID: 5683598

The webcast can be accessed in the "Investors" section of The
Medicines Company website
. A replay of the webcast will also be
available.

About Inclisiran

Inclisiran (formerly known as PCSK9si and ALN-PCSsc) is an
investigational GalNAc-conjugated RNA interference therapeutic targeting
PCSK9 - a genetically validated protein regulator of LDL receptor
metabolism - being developed for the treatment of hypercholesterolemia.
In contrast to anti-PCSK9 monoclonal antibodies (MAbs) that bind to
PCSK9 in blood, inclisiran is a first-in-class investigational medicine
that acts by turning off PCSK9 synthesis in the liver.

The Medicines Company and Alnylam Pharmaceuticals, Inc. are
collaborating in the advancement of inclisiran pursuant to their 2013
agreement. Under the terms of the agreement, Alnylam completed certain
pre-clinical studies and the Phase I clinical study, with The Medicines
Company leading and funding the development of inclisiran from Phase II
forward, as well as potential commercialization.

About The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an
overriding purpose - to save lives, alleviate suffering and contribute
to the economics of healthcare. The Company's goal is to create
transformational solutions to address the most pressing healthcare needs
facing patients, physicians and providers in cardiovascular care. The
Company is headquartered in Parsippany, New Jersey.

Forward-Looking Statements

Statements contained in this press release about The Medicines Company
that are not purely historical, and all other statements that are not
purely historical, may be deemed to be forward-looking statements for
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Without limiting the foregoing, the words
"believes," "anticipates," "plans," "expects" and "potential' and
similar expressions, are intended to identify forward-looking
statements. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the Company's actual results,
levels of activity, performance or achievements to be materially
different from those expressed or implied by these forward-looking
statements. Important factors that may cause or contribute to such
differences include the ability of the Company to effectively develop
inclisiran; whether inclisiran will advance in the clinical trials
process on a timely basis or at all, or succeed in achieving its
specified endpoints; whether the Company will make regulatory
submissions for inclisiran on a timely basis; whether its regulatory
submissions will receive approvals from regulatory agencies on a timely
basis or at all; and such other factors as are set forth in the risk
factors detailed from time to time in the Company's periodic reports and
registration statements filed with the Securities and Exchange
Commission, including, without limitation, the risk factors detailed in
the Company's Annual Report on Form 10-K filed with the SEC on March 1,
2018, which are incorporated herein by reference. The Company
specifically disclaims any obligation to update these forward-looking
statements.

NON-GAAP FINANCIAL PERFORMANCE MEASURES

In addition to financial information prepared in accordance with U.S.
GAAP, this press release also contains adjusted loss from continuing
operations and adjusted loss per share from continuing operations
attributable to The Medicines Company. The Company believes these
measures provide investors and management with supplemental information
relating to operating performance and trends that facilitate comparisons
between periods and with respect to projected information.

Adjusted loss from continuing operations excludes share-based
compensation expense, amortization of acquired intangible assets,
inventory adjustments, restructuring charges, changes in contingent
purchase price, legal settlements and non-cash interest expense. The
Company believes these non-GAAP financial measures help indicate
underlying trends in the Company's business and are important in
comparing current results with prior period results and understanding
projected operating performance. Non-GAAP financial measures provide the
Company and its investors with an indication of the Company's baseline
performance before items that are considered by the Company not to be
reflective of the Company's ongoing results. See the attached
Reconciliations of GAAP to Adjusted Loss from Continuing Operations and
Adjusted Loss per Share for explanations of the amounts excluded and
included to arrive at adjusted net loss and adjusted loss per share
amounts for the three-months ended March 31, 2018 and 2017.

These adjusted measures are non-GAAP and should be considered in
addition to, but not as a substitute for, the information prepared in
accordance with U.S. GAAP. The Company strongly encourages investors to
review its consolidated financial statements and publicly-filed reports
in their entirety and cautions investors that the non-GAAP measures used
by the Company may differ from similar measures used by other companies,
even when similar terms are used to identify such measures.

THE MEDICINES COMPANY

CONSOLIDATED STATEMENTS OF OPERATIONS

UNAUDITED

(In thousands, except per share amounts)

Three Months Ended
March 31,

2018     2017
Net revenues $ 7,771 $ 17,465
Operating expenses:
Cost of product revenues 2,737 9,978
Research and development 40,366 26,444
Selling, general and administrative 28,951   40,457  
Total operating expenses 72,054   76,879  
Loss from operations (64,283 ) (59,414 )
Co-promotion and license income 228 757
Loss on short-term investment (29,989 )
Interest expense (12,077 ) (12,422 )
Other income 2,369   111  
Loss from continuing operations before income taxes (103,752 ) (70,968 )
Benefit (provision) for income taxes 18,916   (28 )
Loss from continuing operations (84,836 ) (70,996 )
Income (loss) from discontinued operations, net of tax 113,985   (31,674 )
Net income (loss) $ 29,149   $ (102,670 )
 
Basic (loss) earnings per common share:
Loss from continuing operations $ (1.14 ) $ (1.00 )
Earnings (loss) from discontinued operations 1.54   (0.44 )
Basic earnings (loss) per share $ 0.40   $ (1.44 )
 
Diluted (loss) earnings per common share:
Loss from continuing operations $ (1.14 ) $ (1.00 )
Earnings (loss) from discontinued operations 1.54   (0.44 )
Diluted earnings (loss) per share $ 0.40   $ (1.44 )
 
Weighted average number of common shares outstanding:
Basic 74,116 71,073
Diluted 74,116 71,073

THE MEDICINES COMPANY

BALANCE SHEET ITEMS

UNAUDITED

(In thousands)

March 31, 2018   December 31, 2017
Cash and cash equivalents $ 215,962 $ 151,359
Short-term investment $ 24,521 $
Total assets $ 861,174 $ 872,983
Convertible senior notes (due 2022 and 2023) $ 655,943 $ 649,198
The Medicines Company stockholders' equity $ 67,656 $ 24,914

THE MEDICINES COMPANY

RECONCILIATIONS OF GAAP TO ADJUSTED LOSS FROM CONTINUING
OPERATIONS AND ADJUSTED LOSS PER SHARE

UNAUDITED

(In thousands, except per share amounts)

Three Months Ended
March 31,

2018   2017
Loss from continuing operations $ (84,836 ) $ (70,996 )
Before tax adjustments:
Cost of product revenues:
Share-based compensation expense (1) (6 ) 171
Amortization of acquired intangible assets (2) 4,486
Inventory adjustments (3) (416 ) (411 )
Restructuring charges (4) 443 (66 )
Research and development:
Share-based compensation expense (1) 984 592
Restructuring charges (4) 326 (108 )
Selling, general and administrative:
Share-based compensation expense (1) 3,449 5,431
Restructuring charges (4) 4,537 (51 )
Changes in contingent purchase price (5) (264 ) 692
Legal settlements (6) 3,550
Other:
Non-cash interest expense (7) 6,745 6,973
Change in short-term investments (8) 28,027
Net loss tax adjustments (9) (18,916 )  
Loss from continuing operations - Adjusted $ (56,377 ) $ (53,287 )
 
Loss per share - Adjusted
Basic $ (0.76 ) $ (0.75 )
Diluted $ (0.76 ) $ (0.75 )
Weighted average number of common shares outstanding:
Basic 74,116 71,073
Diluted 74,116 71,073

Explanation of Adjustments:

(1) Excludes share-based compensation of $4,427 and $6,194 for the three
months ended March 31, 2018 and 2017 because these expenses are
substantially dependent on changes in the market price of the Company's
common stock.

(2) Excludes amortization of intangible assets resulting from the
Incline Therapeutics transaction.

(3) Excludes all non-cash inventory adjustments.

(4) Excludes restructuring charges related to workforce reorganization
initiated in the first quarter 2018 and the sale of the non-core
cardiovascular products.

(5) Excludes changes in fair value of the contingent price related to
the acquisitions of Rempex that were not included in the sale to Melinta.

(6) Excludes net loss from one-time legal settlements in 2018.

(7) Excludes non-cash interest expense which is in excess of the actual
interest expense paid on the Convertible Senior Notes.

(8) Excludes changes in fair value with our investment in Melinta and
guaranteed payments associated with the sale of our infectious disease
business.

(9) Excludes the estimated tax effect related to the sale of Melinta.

In addition to the financial information prepared in accordance with
U.S. GAAP, this press release also contains adjusted financial measures
that the Company believes provide investors and management with
supplemental information relating to operating performance and trends
that facilitate comparisons between periods and with respect to
projected information.
These adjusted measures should be
considered in addition to, but not as a substitute for, the information
prepared in accordance with U.S. GAAP.
The Company strongly
encourages investors to review its consolidated financial statements and
publicly filed reports in their entirety and cautions investors that the
non-GAAP measures used by the Company may differ from similar measures
used by other companies, even when similar terms are used to identify
such measures.

View Comments and Join the Discussion!